An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF) - MACS1632/2254

Trial Profile

An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF) - MACS1632/2254

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Expanded access
  • Acronyms JUMP
  • Sponsors Novartis
  • Most Recent Events

    • 25 Jun 2017 Results (n=416) assessing safety and efficacy of Ruxolitinib in elderly Patients (≥ 75 Years) with myelofibrosis, presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results assessing the safety and efficacy of Ruxolitinib by dynamic IPSS (DIPSS) prognostic risk status (n=1840), presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results of an ad hoc analysis assessing the safety and efficacy of Ruxolitinib using subset of JUMP patients (n=48) who started treatment at 10 mg bid and had the dose uptitrated, presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top